Chemoradiotherapy in pancreatic carcinoma
- PMID: 20596304
- PMCID: PMC2885880
- DOI: 10.4103/0971-5851.60049
Chemoradiotherapy in pancreatic carcinoma
Abstract
Pancreatic cancer patients present late in their course and surgical resection as a modality of treatment is of limited value. Majority develop loco-regional failure and distant metastasis, therefore, adjuvant therapy comprising of radiotherapy and chemotherapy are useful treatment options to achieve higher loco-regional control. Specialized irradiation techniques like intra-operative radiotherapy that help to increase the total tumor dose have been used, however, controvertible survival benefit was observed. Various studies have shown improved median and overall survival with chemoradiotherapy for advanced unresectable pancreatic carcinoma. The role of new agents such as topoisomerase I inhibitors also needs further clinical investigations.
Keywords: Carcinoma; chemoradiation; pancreas.
Conflict of interest statement
References
-
- Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society; 2006. American Cancer Society.
-
- An epidemiological study Cancer Incidence. 1992. National Cancer Registry Program. Population based cancer registries 1988-89; pp. 10–4.
-
- Allema JH, Reinders ME, van Gulik TM, Koelemay MJ, van Leeuwen DJ, de Wit LT, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069. - PubMed
-
- Lowy AM, Leach SD. Adjuvant/neoadjuvant chemoradiation for gastric and pancreatric cancer. Oncology. 1999;5:121. - PubMed
LinkOut - more resources
Full Text Sources